Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Dual Menin and FLT3 Inhibition in Patients With Relapsed/Refractory FLT3- Mutated Acute Myeloid Leukemia Containing a Concurrent MLL-Rearrangement or NPM1 Mutation: A Phase I (Ph I) Study of SNDX-5613 + Gilteritinib

NCT06222580 is registered in ClinicalTrials.gov with Uma Borate as lead sponsor.

NCT NCT06222580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06222580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Dual Menin and FLT3 Inhibition in Patients With Relapsed/Refractory FLT3- Mutated Acute Myeloid Leukemia Containing a Concurrent MLL-Rearrangement or NPM1 Mutation: A Phase I (Ph I) Study of SNDX-5613 + Gilteritinib
Lead sponsor
Uma Borate
Phase
Phase 1
Overall status
Recruiting
Start date
February 20, 2024
Completion date
February 28, 2027
Enrollment
30 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia with flt3/itd mutation, acute myeloid leukemia with kmt2a rearrangement, acute myeloid leukemia with npm1 mutation, recurrent acute myeloid leukemia, refractory acute myeloid leukemia